JPMorgan Chase set a €90.00 ($111.11) price target on Merck KGaA (FRA:MRK) in a research report report published on Tuesday. The firm currently has a neutral rating on the healthcare company’s stock.
A number of other equities analysts have also issued reports on the stock. UBS reiterated a buy rating on shares of Merck KGaA in a research report on Monday, January 15th. Kepler Capital Markets set a €115.00 ($141.98) target price on shares of Merck KGaA and gave the stock a buy rating in a research report on Wednesday, January 17th. Nord/LB reiterated a neutral rating on shares of Merck KGaA in a research report on Wednesday, December 27th. Sanford C. Bernstein set a €115.00 ($141.98) target price on shares of Merck KGaA and gave the stock a buy rating in a research report on Wednesday, January 17th. Finally, Warburg Research set a €115.00 ($141.98) target price on shares of Merck KGaA and gave the stock a buy rating in a research report on Friday, February 16th. Twelve research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of €100.32 ($123.85).
Shares of MRK stock opened at €80.50 ($99.38) on Tuesday. Merck KGaA has a 1 year low of €76.60 ($94.57) and a 1 year high of €115.00 ($141.98).
COPYRIGHT VIOLATION WARNING: “Merck KGaA (MRK) PT Set at €90.00 by JPMorgan Chase” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/07/merck-kgaa-mrk-pt-set-at-90-00-by-jpmorgan-chase.html.
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.